To further investigate roles of APT-1 and -2 in NRAS mutant melanoma, we tested another newly developed drug, palmostatin B. Its different chemical structure may render it less specific, compared to ML349 and ML349 [32,42]. Here, LYPLA1 is linked to melanoma.